Breathe Well Live Well
BioPharma Dive |
Glaxos Eosinophilic Asthma Drug Nucala Wins CHMP Backing
Zacks.com In the U.S., the drug is approved for both COPD and asthma. We note that Glaxo has a collaboration agreement with Theravance for Relvar/Breo Ellipta and Anoro Ellipta (COPD). Relvar/Breo Ellipta generated sales of £94 million in the first half of 2015. After bad news on Breo, Glaxo's monthly asthma drug wins an EU rec |
View full post on asthma – Google News
Medscape |
CHMP Backs Mepolizumab for Severe Eosinophilic Asthma
Medscape The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of mepolizumab (Nucala, GlaxoSmithKline) for add-on maintenance treatment in adults with severe refractory eosinophilic asthma, … EU regulator backs approval for GSK injectable asthma drug GlaxoSmithKline's asthma injection heads for EU approval Glaxo asthma drug clears key hurdle in Europe |
View full post on asthma – Google News
Condition: Eosinophilic Esophagitis
Interventions: Drug: Budesonide effervescent 0.5mg tablet twice daily; Drug: Budesonide effervescent 1mg tablet twice daily; Drug: Placebo effervescent tablet twice daily
Sponsor: Dr. Falk Pharma GmbH
Not yet recruiting – verified July 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Medscape |
FDA Panel Backs Mepolizumab for Severe Eosinophilic Asthma
Medscape A typical characteristic of mild asthma is airway inflammation due to eosinophils, and this inflammation is closely associated with the risk for severe asthma exacerbations. Several products are approved for long-term maintenance treatment of asthma … FDA panel backs approval of GSK asthma drug in adults Asthma Drug Targeting IL-5 Wins Partial Backing From FDA Advisers UPDATE: Glaxo's (GSK) Severe Asthma Drug Mepolizumab Found Effective in … |
View full post on asthma – Google News
|
Eosinophilic Asthma: Reducing Exacerbations and Steroid Use
Medscape This study focused on the use of a novel humanized monoclonal antibody against interleukin-5 (IL-5) in patients with severe eosinophilic-related asthma. We all take care of patients who, despite optimal inhaled therapy and the use of other oral agents … |
View full post on asthma – Google News
|
GSK Files For Approval Of Mepolizumab In US, Europe For Eosinophilic Asthma
Nasdaq The submissions include a Biologics Licence Application to the US Food and Drug Administration as an add-on maintenance treatment for severe eosinophilic asthma in patients aged 12 years and older with a history of exacerbations. It also comprises a … |
View full post on asthma – Google News
Condition: Asthma
Interventions: Biological: Mepolizumab; Drug: Placebo; Drug: SOC
Sponsor: GlaxoSmithKline
Not yet recruiting – verified October 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
2 Minute Medicine |
Mepolizumab reduces exacerbations in severe eosinophilic asthma [MENSA trial]
2 Minute Medicine 1. The rate of asthma exacerbations was significantly reduced in patients with severe eosphinophilic asthma receiving either intravenous or subcutaneous mepolizumab, compared to patients receiving placebo. 2. The safety profile of mepolizumab was … Seven developments in asthma research |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: lebrikizumnab; Other: placebo
Sponsor: Hoffmann-La Roche
Not yet recruiting – verified March 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Asthma more common in eosinophilic esophagitis than previously thought
Family Practice News Digital Network While previous studies have estimated the prevalence of asthma in children with eosinophilic esophagitis (EoE), to range from 24-42%, a recent analysis presented during a late-breaker abstract session at annual meeting of the American Academy of … |
View full post on asthma – Google News